{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:03:54Z","timestamp":1790676234472,"version":"4.1.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Cushing syndrome (CS) is a rare endocrine disorder associated with a markedly increased risk of venous thromboembolism (VTE). Chronic hypercortisolism induces a prothrombotic state through activation of coagulation pathways, impaired fibrinolysis, and endothelial dysfunction. VTE represents a major source of morbidity and mortality in this population, yet optimal strategies for prevention and treatment remain insufficiently standardized. To summarize current evidence on the epidemiology, pathophysiology, risk factors, prevention, and treatment of VTE in patients with endogenous CS and to propose a practical thromboprophylaxis approach. A narrative review of the literature was conducted using MEDLINE\/PubMed, Scopus, and Embase databases. Observational studies, registry data, systematic reviews, and expert consensus statements addressing VTE in CS were analyzed, with particular attention to peri-operative risk and persistence of hypercoagulability after remission. Patients with CS have a 10\u201320-fold higher risk of VTE compared with the general population. The peri-operative period, especially after TSS or adrenalectomy, represents the highest-risk phase, although increased thrombotic risk may persist for 3\u20136 months after biochemical remission. Key mechanisms include elevated factor VIII, von Willebrand factor, plasminogen activator inhibitor-1, increased thrombin generation, and endothelial dysfunction. Recent evidence from the ERCUSYN registry and the 2025 Delphi consensus supports early and extended thromboprophylaxis. Current expert consensus supports low-molecular-weight heparin as the preferred peri-operative pharmacological agent, whereas direct oral anticoagulants may be considered in selected patients during long-term management. CS should be regarded as a persistent prothrombotic condition in which early and, when appropriate, extended thromboprophylaxis should be considered following individualized assessment of thrombotic and bleeding risk. Prospective studies are needed to develop evidence-based, individualized prevention strategies.<\/jats:p>","DOI":"10.3389\/fendo.2026.1927311","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:41:55Z","timestamp":1790674915000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Venous thromboembolism in Cushing syndrome: current evidence and a practical thromboprophylaxis algorithm"],"prefix":"10.3389","volume":"17","author":[{"given":"Pawe\u0142","family":"Kuca","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Endocrinology and Diabetes, Mazovian Brodnowski Hospital","place":["Warsaw, Poland"]},{"name":"Department of Internal Medicine, Endocrinology and Diabetes, Medical University of Warsaw","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Kostrzewska","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Endocrinology and Diabetes, Mazovian Brodnowski Hospital","place":["Warsaw, Poland"]},{"name":"Department of Internal Medicine, Endocrinology and Diabetes, Medical University of Warsaw","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Migda","sequence":"additional","affiliation":[{"name":"Diagnostic Ultrasound Lab, Department of Pediatric Radiology, Medical University of Warsaw","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemys\u0142aw","family":"Witek","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Endocrinology and Diabetes, Mazovian Brodnowski Hospital","place":["Warsaw, Poland"]},{"name":"Department of Internal Medicine, Endocrinology and Diabetes, Medical University of Warsaw","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-024-02453-9","article-title":"Hypertension and Cushing\u2019s syndrome: hunt for the red flag","volume":"48","author":"Martino","year":"2025","journal-title":"J Endocrinol Invest"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0125","article-title":"The diagnosis of Cushing\u2019s syndrome: an Endocrine Society Clinical Practice Guideline","volume":"93","author":"Nieman","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-0290","article-title":"Hypercoagulable state in Cushing's syndrome: a systematic review","volume":"94","author":"Van Zaane","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1661","article-title":"Incidence of venous thromboembolism in patients with Cushing's syndrome: a multicenter cohort study","volume":"96","author":"Stuijver","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvad176","article-title":"High prevalence of venous thrombotic events in Cushing's syndrome: data from ERCUSYN and details in relation to surgery","volume":"190","author":"Isand","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2024.08.090","article-title":"Venous thromboembolism and prevention strategies in patients with Cushing's disease: a systematic review","volume":"191","author":"White","year":"2024","journal-title":"World Neurosurg"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-014-0600-y","article-title":"Perioperative thromboprophylaxis in Cushing's disease: what we did and what we are doing","volume":"18","author":"Barbot","year":"2015","journal-title":"Pituitary"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-022-01261-9","article-title":"Hypercoagulability in Cushing's syndrome: incidence, pathogenesis and need for thromboprophylaxis protocols","volume":"25","author":"Feelders","year":"2022","journal-title":"Pituitary"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvaf017","article-title":"Delphi panel consensus on recommendations for thromboprophylaxis of venous thromboembolism in endogenous Cushing's syndrome: a position statement","volume":"192","author":"Isand","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2753","article-title":"The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy","volume":"97","author":"van der Pas","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1159\/000314349","article-title":"Coagulopathy in Cushing\u2019s syndrome","volume":"92","author":"Trementino","year":"2010","journal-title":"Neuroendocrinology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345709","article-title":"Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels","volume":"32","author":"Erem","year":"2009","journal-title":"J Endocrinol Invest"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.33549\/physiolres.931126","article-title":"Impaired microvascular reactivity and endothelial function in patients with Cushing's syndrome: influence of arterial hypertension","volume":"57","author":"Pr\u00e1zn\u00fd","year":"2008","journal-title":"Physiol Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1159\/000318566","article-title":"Cardiovascular disease in Cushing's syndrome: heart versus vasculature","volume":"92","author":"De Leo","year":"2010","journal-title":"Neuroendocrinology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2020.04.004","article-title":"The immune system in Cushing's syndrome","volume":"31","author":"Hasenmajer","year":"2020","journal-title":"Trends Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/ani13081299","article-title":"Role of prednisolone in platelet activation by inhibiting TxA2 generation through the regulation of cPLA2 phosphorylation","volume":"13","author":"Kim","year":"2023","journal-title":"Animals"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1983.tb00025.x","article-title":"Thromboembolic complications in Cushing's syndrome","volume":"19","author":"Small","year":"1983","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-30070-8","article-title":"Prevalence of perioperative asymptomatic venous thromboses of the lower extremity in 30 consecutive patients undergoing transsphenoidal surgery for Cushing's disease","volume":"13","author":"Huckhagel","year":"2023","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)00086-3","article-title":"Complications of Cushing's syndrome: state of the art","volume":"4","author":"Pivonello","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12959-023-00515-1","article-title":"Preventive strategies for hypercoagulation in Cushing's syndrome: when and how","volume":"21","author":"Lopes","year":"2023","journal-title":"Thromb J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000840","article-title":"DOACs vs LMWHs in hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH guidelines","volume":"4","author":"Neumann","year":"2020","journal-title":"Blood Adv"},{"key":"B22","doi-asserted-by":"publisher","first-page":"X1","DOI":"10.1093\/ejendo\/lvaf017","article-title":"Delphi panel consensus on recommendations for thromboprophylaxis of venous thromboembolism in endogenous Cushing's syndrome: a position statement","volume":"192","author":"Reincke","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1055\/s-0037-1613747","article-title":"High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism","volume":"83","author":"Kraaijenhagen","year":"2000","journal-title":"Thromb Haemost"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-066846","article-title":"Drug\u2013drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case-control study in the National COVID Cohort Collaborative (N3C)","volume":"12","author":"Kravchenko","year":"2022","journal-title":"BMJ Open"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14061120","article-title":"Drug\u2013drug interactions of direct oral anticoagulants (DOACs): from pharmacological to clinical practice","volume":"14","author":"Ferri","year":"2022","journal-title":"Pharmaceutics"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.122","article-title":"Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study","volume":"173","author":"Johannesdottir","year":"2013","journal-title":"JAMA Intern Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1415","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","author":"Waljee","year":"","journal-title":"BMJ"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.7326\/M20-0432","article-title":"Association between oral corticosteroid bursts and severe adverse events: a nationwide population-based cohort study","volume":"173","author":"Yao","year":"2020","journal-title":"Ann Intern Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.04034.x","article-title":"Systematic review on the effect of glucocorticoid use on procoagulant, anticoagulant and fibrinolytic factors","volume":"8","author":"van Zaane","year":"2010","journal-title":"J Thromb Haemost"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17388","article-title":"Glucocorticoid use and risk of first and recurrent venous thromboembolism: self-controlled case-series and cohort study","volume":"193","author":"Orsi","year":"2021","journal-title":"Br J Haematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0272","article-title":"The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics","volume":"165","author":"Valassi","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.5603\/EP.a2016.0034","article-title":"Cushing`s disease: Fibrinogen and D-dimer levels fail to normalize despite early postoperative remission - a prospective, controlled study","volume":"67","author":"Witek","year":"2016","journal-title":"Endokrynol Pol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-009-9186-y","article-title":"Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers","volume":"36","author":"Kastelan","year":"2009","journal-title":"Endocrine"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-015-0665-z","article-title":"A venous thromboembolism risk assessment model for patients with Cushing's syndrome","volume":"52","author":"Zilio","year":"2016","journal-title":"Endocrine"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2016.06.087","article-title":"Coagulation profile dynamics in pediatric patients with Cushing syndrome: A prospective, observational comparative study","volume":"177","author":"Birdwell","year":"2016","journal-title":"J Pediatr"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1350010","article-title":"The thrombotic risk in Cushing's syndrome-questions, answers, and the algorithm to consider in its assessment: part I-thrombotic risk not related to surgery","volume":"15","author":"Bryk-Wi\u0105zania","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-022-01258-4","article-title":"Cardiovascular health and mortality in Cushing's disease","volume":"25","author":"Coulden","year":"2022","journal-title":"Pituitary"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1927311\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:41:56Z","timestamp":1790674916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1927311\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":37,"alternative-id":["10.3389\/fendo.2026.1927311"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1927311","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"article-number":"1927311"}}